Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (<i>EGFR)</i> mutation-positive metastatic non-small cell lung cancer (NSCLC) in recent years. Originally, it was approved for second-line treatment after epidermal growth factor receptor <i>EGFR</i> tyrosin...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Markus Falk, Stefanie Schatz, Fabian P. M. Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2023-09-01
Serija:	Current Oncology
Teme:	disease monitoring <i>EGFR</i> hybrid capture NGS osimertinib liquid biopsy
Online dostop:	https://www.mdpi.com/1718-7729/30/10/640
Oznake:	Označite Brez oznak, prvi označite!